# Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring

> **NCT04194827** · PHASE4 · UNKNOWN · sponsor: **Reade Rheumatology Research Institute** · enrollment: 267 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DIAGNOSTIC_TEST:** Adalimumab serum trough concentration
- **DIAGNOSTIC_TEST:** Disease activity
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT04194827
- **Lead sponsor:** Reade Rheumatology Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-01
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 267 (ESTIMATED)
- **Last updated:** 2024-04-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04194827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04194827, "Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04194827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*